Currently, neurofilaments (NF), which are increased in CSF and blood of ALS patients as consequence of motor neuron damage [18], are largely accepted as biomarkers for ALS; they constitute benchmark biomarkers and have been used in clinical trials [19]. This evidence concerns the gene NFASC and amyotrophic lateral sclerosis.